2022年4月7日,国家局网站更新键嘉骨科手术机器人获批消息,根据国家药品监督管理局网站数据,目前已有151个创新医疗器械获批上市产品。
其中值得一提的是,2021年共有35个创新医疗器械产品上市,总量相比2020年增加了35%。而自2022年以来,已有17款创新医疗器械产品获NMPA批准上市。下面我们一起看看获批的创新医疗器械都有哪些吧。
151个创新医疗器械获批上市产品目录
| | | | | | | | | | | | | | | | | | | | | | | | | MTHFR C677T 基因检测试剂盒(PCR-金磁微粒层析法) | | | | | | | | Septin9基因甲基化检测试剂盒(PCR荧光探针法) | | | | | | | | 运动神经元存活基因1(SMN1)外显子缺失检测试剂盒(荧光定量PCR法) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 人类EGFR基因突变检测试剂盒(多重荧光PCR法) | | | | | | | | | | | | | | | | | | | | | | | | | | | | 人EGFR/ALK/BRAF/KRAS基因突变联合检测试剂盒(可逆末端终止测序法) | | | | | | | | 人EGFR、KRAS、BRAF、PIK3CA、ALK、ROS1基因突变检测试剂盒(半导体测序法) | | | | | | | | | | | | EGFR/ALK/ROS1/BRAF/KRAS/HER2基因突变检测试剂盒(可逆末端终止测序法) | | | | | | | | | | | | | | | | 人类10基因突变联合检测试剂盒(可逆末端终止测序法) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 经导管植入式无导线起搏系统Micra Transcatheter Leadless Pacemaker system | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 人EGFR/KRAS/BRAF/HER2/ALK/ROS1基因突变检测试剂盒(半导体测序法) | | | | 胚胎植入前染色体非整倍体检测试剂盒(半导体测序法) | | | | | | | | | | | | | | | | RNF180/Septin9基因甲基化检测试剂盒(PCR荧光探针法) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | KRAS基因突变及BMP3/NDRG4基因甲基化和便隐血联合检测试剂盒(PCR荧光探针法-胶体金法) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 幽门螺杆菌23S rRNA基因突变检测试剂盒(PCR-荧光探针法) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | W.L. Gore & Associates, Inc. | | | | | | | 胚胎植入前染色体非整倍体检测试剂盒(可逆末端终止测序法) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
------------------------------------------------------------------------------
|